



## NEWS RELEASE

### **For Further Information Contact:**

Roy Wolvin

Nymox Pharmaceutical Corporation

800-93NYMOX

[www.nymox.com](http://www.nymox.com)

### **For Immediate Release:**

## **Nymox Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 Investigational Drug for BPH**

HASBROUCK HEIGHTS, NJ (November 19, 2008) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the NEXUS-1 and NEXUS-2 Phase 3 clinical trials for NX-1207, the Company's new drug for benign prostatic hyperplasia (BPH).

The NEXUS-1 and NEXUS-2 trials are the Company's pivotal Phase 3 North American clinical studies for NX-1207. It is anticipated that the trials will enroll over 800 subjects and involve 50-100 investigational sites. Currently the Company is in the process of site recruitment at over 60 locations throughout the U.S. In addition, several hundred men with BPH have contacted the Company to express interest in participating in the NX-1207 clinical trial.

In blinded US Phase 2 clinical trials to date, NX-1207 has proven to be both safe and efficacious in the treatment of BPH, a common affliction of older men. A single administration of NX-1207 2.5 mg produced on average improvements in the standardized BPH symptom score that were approximately double that reported for currently approved BPH drugs. Men treated with NX-1207 reported an improvement in their BPH symptoms one or two weeks after a single NX-1207 treatment. After 3 months, the average improvement in BPH symptom score was 10.3 points (44% improvement from baseline). This improvement was statistically significant as compared to controls.

NX-1207 treatment has not been associated with the side effects associated with currently approved BPH drugs, which can include retrograde ejaculation, sudden drops in blood pressure, loss of sex drive and other adverse reactions.

Follow-up studies of available subjects from the NX-1207 clinical trials have provided evidence of durable benefits from NX-1207 treatment for up to 4½ years from the date of treatment. In a recently completed study, 76.7% of men receiving a single treatment of NX-1207 2.5 mg reported requiring no further treatment for their BPH more than a year later (statistically significant compared to controls  $p=.012$ ). These men after 1 year maintained on average an improvement of 38% in their BPH Symptom Scores.

BPH is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of older men and can lead to acute urinary retention, incontinence, and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

###